INTRODUCTION
Malaria is an infectious disease caused by the members of the genus Plasmodium and is responsible for 2 million annual deaths worldwide (1) . According to the latest estimates from the World Health Organization (WHO), there were 214 million new cases of malaria worldwide in 2015 (range 149-303 million). The African region accounted for most global cases of malaria (88%), followed by the South-East Asia region (10%) and the Eastern Mediterranean region (2%) (2) . As a result of a highly intense anti-Plasmodium campaign carried out by governmental organizations during the past decade, malaria is now restricted in the southeastern region of Turkey as a sporadic disease caused by P. vivax. However, recently P. falciparum malaria is also diagnosed among the travelers to sub-Saharan Africa. Further, P. falciparum malaria can cause severe complications such as deep anemia, cerebral malaria, seizures, hypoglycemia, acute kidney failure, pulmonary edema, lactic acidosis, and death in the absence of prompt and effective treatment (3, 4) . Therefore, P. falciparum malaria needs intense treatment with appropriate anti-malarial drugs as well as with supportive measures such as transfusion of blood and blood products. Post-transfusion complications may interfere with the symptoms and signs of malaria and further complicate the course of the disease.
Transfusion-related acute lung injury (TRALI) is a severe posttransfusion reaction that manifests as acute unset of dyspnea and tachypnea within 6 hours of infusion of blood products. It is currently considered to be a major complication of transfusion. Early recognition of the clinical symptoms may reduce the morbidity and mortality (5) . Here we present a case of TRALI syndrome developed during the treatment of P. falciparum malaria.
CASE REPORT
A 29-year-old male resident of Turkey was admitted to a hospital 15 days after returning from a business trip to Burkina Faso with high fever and sweating. He had been admitted to another provincial hospital. The patient was diagnosed with malaria and treated with chloroquine for a total of 6 days. He was later admitted to our hospital due to lack of improvement in his general condition.
His general condition was poor when he was admitted to our hospital. His physical examination revealed 2 cm of splenomegaly, and his body temperature was 37.6°C. His other systemic examination findings were normal. Laboratory results were hemoglobin: 12.3 g/dL, platelets: 164000/mm 3 , urea: 201 mg/dL, creatinine: 3.4 mg/dL, ALT: 44 U/L, AST: 52 U/L, LDH: 530 U/L, total protein: 6.3 g/dL, albumin: 2.8 g/dL, CRP: 161 mg/l, sedimentation: 53/hour, INR: 1.6, total bilirubin: 0.77 mg/dL, and direct bilirubin: 0.65 mg/dL. P. falciparum sporozoites were observed in blood film examination. We started treatment with intramuscular injection of artemether. The patient suddenly developed respiratory failure after being given a unit of fresh frozen plasma because of the prolongation of prothrombin time. Oxygen saturation was 85% in room air. Chest radiograph revealed bilateral diffuse opacities, and the patient's echocardiography findings were normal (Figure 1 ). The patient was transferred to the intensive care unit (ICU), and his breathing improved gradually under non-invasive ventilatory support in 48 hours. He was then transferred to the inpatient ward.
Plasmodium became undetectable in blood film preparations on the 4 th day of treatment. The patient continued to have high fever. Because his hemoglobin level was 6 g/dL, after hematology consultation, two units of washed erythrocytes suspension were given. This time, he did not develop lung injury. After the 9 th day of admission, the fever started to subside, while his hemoglobin level increased to 8.4 g/dL. He was discharged on the 18 th day. Informed consent has taken from patient for case report.
DISCUSSION
Malaria is an overwhelming problem in developing countries in tropical regions. It is estimated that up to 40% of the world's population is at risk of developing malaria. In sub-Saharan Africa, most severe cases and deaths occur among children younger than 5 years of age and among pregnant women.
According to the data collected by the Republic of Turkey Ministry of Health, P. vivax is endemic to southeastern Turkey and other types of Plasmodium sporadically surface in other regions, while P. falciparum is rare (1) . P. falciparum malaria that is related to international travel has been seen in Turkey in recent years (1). Our patient who was a resident of Turkey traveled to Burkina Faso and was admitted to a hospital 15 days after returning. P. falciparum malaria can be fatal if not diagnosed and treated promptly. This is especially true in case of non-immune travelers returning from visits to malaria-endemic areas. Severe malaria is associated with the rapid development because anemia-infected, once-infected, and uninfected erythrocytes are hemolytic and removed from the circulation by the spleen (2). Replacement of blood and fluids may lead to rapid reductions in lactate levels, resolution of metabolic acidosis, improvement in renal function, and clinical improvement in critically ill patients (3). TRALI is a rare but potentially fatal complication of blood product transfusions, which occurs in one in about 5000 transfused blood components. The reported numbers may not reflect the real incidence rates due to unfamiliarity with the syndrome (6, 7).
Severe respiratory distress during or within 6 hours of blood transfusion, pulmonary edema, and hypoxemia with normal left ventricular function should be suggestive of TRALI syndrome. TRALI can occur with all blood components, including plasma, platelets, and intravenous immunoglobulin (IVIG) (8, 9) . Other causes of pulmonary edema should be excluded within TRALI diagnosis, and ARDS, pneumonia, heart failure, volume overload, and acute hemolytic reactions must be considered in differential diagnosis (12, 13) . The number of diagnosed TRALI cases in Turkey is low, potentially because of lack of full diagnosis capabilities and non-infection-related blood transfusions sources of these cases (10-13). Our case was diagnosed with TRALI because respiratory problems were developed soon after plasma transfusion (lower than 90% oxygen saturation within 6 hours) and bilateral effusion was observed on chest radiograph, echocardiographic findings were normal, and symptoms were healed with 48 hours of support treatment, while all lung indicators were normal before the transfusion of fresh frozen plasma to support the treatment of the serious P. falciparum case (Figure 1, 2) .
In the diagnosis of TRALI syndrome, awareness of the existence of this syndrome is the most important, followed by early diagnosis (5, 6) . Mechanical ventilation may be required in the treatment of a severe form of TRALI syndrome, while supplemental oxygen is sufficient in milder forms. Benefits of diuretics and corticosteroids have not been detected. The majority of patients are healed uneventfully within 96 hours. A small group of patients face pulmonary infiltration longer than 7 days, and in 10% of patients, the disease has been found to result in mortality despite all the supportive treatments (7).
Improvement in our patient's condition was caused by respiratory support in the ICU without the need of mechanical ventilation. Collecting plasma from men only or from women who were never pregnant and limiting unnecessary transfusion are recommended for the prevention of TRALI syndrome (8).
CONCLUSION
Our goal was to raise awareness by presenting this case because of significantly reduced mortality rates when the diagnosis of TRALI syndrome is considered in those who develop sudden respiratory distress after the transfusion of blood and blood products.
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